Neuralstem Added to the Russell Microcap® Index
June 26 2017 - 8:32AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that it has been added to the Russell Microcap® Index as
part of the FTSE’s annual reconstitution of its family of U.S.
indexes. The addition will take effect after the U.S. market opens
on June 26.
The Russell Microcap® Index measures the performance of the
microcap segment of the U.S. equity market. Microcap stocks make up
less than 3 percent of the U.S. equity market (by market cap) and
consist of the smallest 1,000 securities in the small-cap Russell
2000® Index, plus the next 1,000 smallest eligible securities by
market cap.
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. Neuralstem’s lead
asset, NSI-189, is an oral antidepressant in Phase 2 clinical
development for major depressive disorder (MDD). NSI-566 is a
stem cell therapy being tested in stroke, chronic spinal cord
injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS).
Neuralstem’s diversified portfolio of product candidates is based
on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and the Form 10-Q for the three
months ended March 31, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Contact:
Danielle Spangler
Investor Relations
Neuralstem, Inc
301.366.1481
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
Lori Rosen
Public Relations
LDR Communications
917.553.6808
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024